Gubra A/S (CO:GUBRA) — Market Cap & Net Worth
Market Cap & Net Worth: Gubra A/S (GUBRA)
Gubra A/S (CO:GUBRA) has a market capitalization of $857.67 Million (Dkr5.48 Billion) as of May 9, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #9895 globally and #47 in its home market, demonstrating a 5.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gubra A/S's stock price Dkr335.40 by its total outstanding shares 16344150 (16.34 Million). Analyse GUBRA cash flow conversion to see how efficiently the company converts income to cash.
Gubra A/S Market Cap History: 2023 to 2026
Gubra A/S's market capitalization history from 2023 to 2026. Data shows growth from $319.65 Million to $857.67 Million (43.39% CAGR).
Gubra A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gubra A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.00x
Gubra A/S's market cap is 6.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $319.65 Million | $205.00 Million | -$44.52 Million | 1.56x | N/A |
| 2024 | $1.60 Billion | $265.74 Million | -$36.50 Million | 6.00x | N/A |
Competitor Companies of GUBRA by Market Capitalization
Companies near Gubra A/S in the global market cap rankings as of May 9, 2026.
Key companies related to Gubra A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #225 globally with a market cap of $107.83 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $73.68 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #225 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.83 Billion | $425.00 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.68 Billion | $709.10 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €232.80 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Gubra A/S Historical Marketcap From 2023 to 2026
Between 2023 and today, Gubra A/S's market cap moved from $319.65 Million to $ 857.67 Million, with a yearly change of 43.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr857.67 Million | -35.19% |
| 2025 | Dkr1.32 Billion | -17.07% |
| 2024 | Dkr1.60 Billion | +399.20% |
| 2023 | Dkr319.65 Million | -- |
End of Day Market Cap According to Different Sources
On May 8th, 2026 the market cap of Gubra A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $857.67 Million USD |
| MoneyControl | $857.67 Million USD |
| MarketWatch | $857.67 Million USD |
| marketcap.company | $857.67 Million USD |
| Reuters | $857.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more